Navigation Links
Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Date:12/13/2007

CAMBRIDGE, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that its Late Onset Treatment Study (LOTS) of Myozyme(R) (alglucosidase alfa) met its co-primary efficacy endpoints. The study was undertaken to evaluate the safety and efficacy of Myozyme in juvenile and adult patients with Pompe disease. Myozyme was first approved in 2006, and the product is now registered in 36 countries.

The randomized, double-blind, placebo-controlled study enrolled 90 patients at eight primary sites in the United States and Europe. Participants received either Myozyme or a placebo every other week for 18 months. The average age of study participants was 44 years. The primary efficacy endpoints of the study sought to determine the effect of Myozyme on functional endurance as measured by the six-minute walk test and to determine the effect of Myozyme on pulmonary function as measured by percent predicted forced vital capacity.

The results showed that, at 18 months, patients treated with Myozyme increased their distance walked in six minutes by an average of approximately 30 meters as compared with the placebo group (P=0.0283; Wilcoxon test). The placebo group did not show any improvement from baseline. The average baseline distance walked in six minutes in both groups was approximately 325 meters.

Percent predicted forced vital capacity in the group of patients treated with Myozyme increased by 1 percent at 18 months. In contrast, it declined by approximately 3 percent in the placebo group (P=0.0026; Wilcoxon test). The average baseline percent predicted forced vital capacity in both groups was approximately 53 percent.

The results for both efficacy endpoints were consistent across various prosp
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  Ten of the ... of cartilage repair, regeneration, allograft reconstruction and research ... the world gathered to discuss the future of ... of Regenerative Medicine symposium, Cartilage Regeneration: State ... included Orthopedic Biosurgery, Minced Juvenile Allograft, and State ...
(Date:9/29/2014)... 29, 2014 Research and Markets  has ... Gas Analyzer, and Gas Chromatograph Market by Type , ... Global Trends & Forecast to 2013 - 2020" ... analyzer is a process analytical instrument that provides chemical ... redefined the way by which companies carry out their ...
(Date:9/29/2014)... NEW YORK , Sept. 29, 2014 /PRNewswire/ ... firm, and The Channel Group ("TCG"), a leader ... transition advisors, have formed an alliance to expand ... to prospective clients. With the alliance, Burnham Securities ... in the scientific, clinical medicine and management in ...
(Date:9/29/2014)... Israel , September 29, 2014 ... novel immunomodulators for severe infections, today announced that the ... has awarded Atox Bio with a contract valued up ... of AB103 to treat Necrotizing Soft Tissue Infections (NSTI) ... threats that end in sepsis. BARDA awarded ...
Breaking Biology Technology:World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2
... IDIX ) announced today that Idenix management will ... Health Care Conference on Monday, May 18, 2009 at 8:40 ... webcast of the company presentation can be accessed under "Calendar ... www.idenix.com . Please log in approximately 5-10 minutes ...
... Trait Will Benefit Everyone from Farmers to Consumers. , ... Wilmington, DE ... reached a regulatory milestone for its next generation of healthier soybean products. ... Canada and the Canadian Food Inspection Agency that its ...
... WHAT: GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, ... company developing human, ... Virus) and other infectious agents to share their strategy for, ... plans to expand preventative trials, currently in, ...
Cached Biology Technology:DuPont Receives Canadian Regulatory Approval for High Oleic Soybean Trait 2DuPont Receives Canadian Regulatory Approval for High Oleic Soybean Trait 3
(Date:9/29/2014)... According to a NASA story from 2009, "human activities in ... fire emissions issue. Palm oil is increasingly grown for use ... fats in processed foods. It has become the most widely ... in recent years to surpass that of soybean oil. , ... has to be cleared to grow the crop, and the ...
(Date:9/29/2014)... get a bad rap, and understandably so. The grain-of-rice-sized ... of millions of acres in the Western U.S. and ... to popular belief, these pests may not be to ... recently swept through the region. Instead, weather and topography ... fires than these bark-boring beetles. , New research led ...
(Date:9/29/2014)... A review article published online in Behavioral Brain ... in the brain as a result of chronic alcohol ... cycle. , Clinical assessments and research indicate that ... disrupted sleep. This can occur when people are actively ... they are abstaining. , "Sleep-wake disturbances can last ...
Breaking Biology News(10 mins):Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... civilian personnel from the U.S. Armed Forces, as well ... and other first-responder personnel from throughout the United States, ... attend the 2009 Force Protection Equipment Demonstration (FPED VII). ... and Marine Corps Base, Quantico, VA, during May 19-21.The ...
... Team Up to Provide High Volume Transaction Solution ... Calif. and NEW YORK, May 11 Communication ... CICI), a leading supplier of electronic signature solutions ... and the recognized leader** in biometric signature verification ...
... EfficiencyWALL, N.J., May 19 BIO-key International, ... in finger-based biometric identification and wireless public ... are deploying BIO-key,s WEB-key(R) biometric identification software ... charging, or eCharging system.(Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ...
Cached Biology News:Demonstration Features Commercial Technology for Combating Terrorism 2Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 2Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 3Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 4Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 5Minnesota Counties Secure New Criminal Charging System With BIO-key(R) Fingerprint Biometrics 2Minnesota Counties Secure New Criminal Charging System With BIO-key(R) Fingerprint Biometrics 3
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Prepared by a modification of the ... Biotechnol. Bioeng., 11 , ... will yield an A 260 ... water (1 cm light path). Physical ...
... Dithiothreitol DTT White solid.. PACKAGED UNDER ... thiols, so reaction is "driven" to completion. A ... waxy surfactant found in many other preparations. Blocks ... Purity: ≥97% by titration. Contaminants: Heavy ...
Biology Products: